Strata Oncology, developer of a range of DNA- and RNA-based tests as well as a genomic and transcriptomic profiling platform, is extending its clinical collaboration with Pfizer assessing multiple approved cancer therapies.
The collaboration is part of the Strata Precision Indications for Approved Therapies (PATH) trial. The 700-participant pan-tumor therapeutic trial is designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.
As part of the trial, Pfizer is providing Braftovi, Mektovi and Lorbrena for up to six new cohorts of patients with early-stage lung, melanoma, colorectal and other cancers who have evidence of micrometastatic disease after initial treatment.
The big pharma has already been providing the same drugs along with Talzenna and Inlyta for evaluation in four late-stage cohorts of the Strata PATH trial.
“The new cohorts of Strata PATH, supported by Pfizer, afford us a very exciting opportunity to move the advances we’ve seen in late-stage cancer into earlier stages of the disease,” Strata CEO Dan Rhodes said in a Sept. 13 release. “Our goal is to deliver smarter and earlier treatment to every patient.”
The bulk of the patients for the new micrometastatic cohorts will be identified through the Strata SentinelTM trial, a separate study spanning 100,000 patients that is assessing Strata's circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) test.
As part of the MRD test a molecular therapy selection profile is created simultaneously for every patient, allowing for faster identification of clinical trial opportunities for patients who are positive for ctDNA.